

From: OC GCP Questions
Sent: Friday, October 30, 2015 12:20 PM
To: [REDACTED]
Subject: RE: background therapy and SOC

Dear [REDACTED],

I am not aware of any regulation mandating that the sponsor financially provide the background therapy or Standard of Care specified in a clinical trial; however as with the requirements of the investigational product, any costs that are passed on to the subject must be disclosed in the informed consent document [21 CFR 50.25(b)(3)]. Additional information regarding charging for investigational products can be found in the following guidance documents:

Draft Guidance on Charging for Investigational Drugs Under an IND – Qs & As :

<http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm351264.pdf>

Information Sheet on Charging for Investigational Products :

<http://www.fda.gov/RegulatoryInformation/Guidances/ucm126427.htm>

I hope that this information is helpful. Please contact us at gcp.questions@fda.hhs.gov if you have further questions. Since many questions and concerns regarding good clinical practices have been addressed over time, some individuals may find it useful to access a set of redacted GCP inquiries found at the following web address:

<http://www.fda.gov/ScienceResearch/SpecialTopics/RunningClinicalTrials/RepliestoInquiriesToFDAonGoodClinicalPractice/default.htm> .

Sincerely,

Bridget A. Foltz, MS, MT(ASCP)
Policy Analyst, Office of Good Clinical Practice
Office of the Commissioner, Food and Drug Administration

This communication does not constitute a written advisory opinion under 21 CFR 10.85, but rather is an informal communication under 21 CFR 10.85(k) which represents the best judgment of the employee providing it. This information does not necessarily represent the formal position of FDA, and does not bind or otherwise obligate or commit the agency to the views expressed.

From: [REDACTED]
Sent: Friday, October 23, 2015 4:23 PM
To: OC GCP Questions
Subject: background therapy and SOC

Hi – is there a regulatory requirement for a Sponsor to provide (without charge or by reimbursing investigative sites) and background therapy or Standard of Care specified in a clinical trial? This assumes that the background med and SOC are approved products marketed in the US.

I am aware that this is typically done but am not aware of any regulation mandating this financial study consideration.

Thanks for your help –

[REDACTED]